as 05-17-2024 4:00pm EST
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Founded: | 2006 | Country: | United States |
Employees: | N/A | City: | REDWOOD CITY |
Market Cap: | 181.6M | IPO Year: | 2014 |
Target Price: | $34.40 | AVG Volume (30 days): | 264.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -10.20 | EPS Growth: | N/A |
52 Week Low/High: | $7.40 - $29.70 | Next Earning Date: | 05-09-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ADVM Breaking Stock News: Dive into ADVM Ticker-Specific Updates for Smart Investing
GuruFocus.com
9 days ago
Zacks
9 days ago
Associated Press Finance
10 days ago
GlobeNewswire
10 days ago
Zacks
10 days ago
GlobeNewswire
16 days ago
Zacks
17 days ago
MT Newswires
19 days ago